Prime Medicine Reports Third Quarter 2025
[ad_1] -- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647…
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
[ad_1] Prime Medicine, Inc. -- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- …
Prime Medicine Reports Third Quarter 2025 Financial Results
[ad_1] -- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647…
Prime Medicine Appoints Matthew Hawryluk as Chief Business Officer
[ad_1] Prime Medicine (Nasdaq: PRME) appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer effective Nov 3, 2025. Dr. Hawryluk will lead corporate and business development, corporate…